UK, EU & ME Life Sciences: 2026 Regulatory Outlook

The global life sciences regulatory landscape is looking to undergo significant evolution in 2026. The UK’s Medicines for Human Use (Clinical Trials) Amendment Regulations 2025 introduce risk-based trial oversight and extended data retention, while the EU’s Commission Decision (EU) 2025/2371 mandates EUDAMED module activation and tighter device registration requirements. At the same time, the EMA is revising GMP Annex 11 and adding Annex 22 to strengthen controls over computerized systems and AI/ML in manufacturing. Across the Middle East, GCC nations are harmonizing medical device regulations with EU MDR/IVDR standards, and Saudi Arabia’s SFDA has rolled out sweeping updates in 2024 and 2025—from biosimilar guidelines to clinical trial modernization and pricing reforms—signaling a region-wide push for regulatory rigor and innovation. 

UK Clinical Trial Regulations 

The UK’s new Medicines for Human Use (Clinical Trials) Amendment Regulations 2025 is set to take effect in April 2026.  

As a part of this update, the term for approved clinical trial changes is being updated from amendments to modifications, reflecting the term used in the EU. This is further classified to substantial, important detail, and minor modifications, denoting their various levels of impact. Additionally, trial master files must now be kept for 25 years. Like the US, there will also be additional ICH harmonization, with this case being E6(R3) integration for marketing authorization trials. For increased transparency, it will be legally required to register clinical trials publicly and clinical trial organizers must offer a digestible summary of trial results with participants. 

Companies conducting clinical trials in the UK should adapt trial operations and documentation to a risk-based, flexible structure, keeping in mind the new document storage and public sharing requirements. It will also be helpful to implement training on modification classifications and ICH E6(R3) requirements. More information on this update can be found through the NHS website.

EU Regulatory Updates 

Mandatory EUDAMED Modules 

The Commission Decision (EU) 2025/2371, made on 26 November 2025 established that four European Database on Medical Devices (EUDAMED) modules will be made into effect in May 2026. 

The four mandatory EUDAMED modules are: 

• Actor registration 

• Unique Device Identifier (UDI)/Devices registration 

• Notified Bodies & Certificates 

• Market Surveillance 

For legacy device makers, they will have until the end of November 2026 to register their legacy devices; new devices will have to be registered in EUDAMED before being marketed when this update comes into effect. Device manufacturers operating in the UK must register and maintain data in EUDAMED to ensure market access. More information on this update can be found through the European Commission website.  

EMA GMP Annex 11 & Annex 22 Revisions 

The EMA’s revisions to GMP Annex 11 and the new addition of Annex 22 are expected to be finalized in mid-2026.  

Annex 11 updates establish additional requirements for computerized systems, including quality risk management principles like mandatory realtime audit trails, lifecycle data governance, and enhanced riskbased validation. There will also be enhanced oversight of suppliers and external providers along with increased requirements for system security through data integrity and electronic signatures. 

Annex 22 is a new annex on artificial intelligence, which establishes the requirements that AI and machine learning must meet to be used in drug manufacturing. The comprehensive requirements include criteria for AI model selection, training, and validation, along with performance metrics, training data quality, and data management and processing. Additionally, human oversight, change controls, and AI performance monitoring are all covered in Annex 22. 

For companies following Annex 11, actions like system audits, and establishing lifecycle control and data governance procedures will be useful to become compliant with the updates. 

The addition of Annex 22 is monumental in scope for companies looking to adopt AI in their ecosystem. To start, companies should define validation and oversight frameworks for their AI and machine learning tools. Static deterministic models will be allowed in critical GMP applications under Annex 22, so intended use and acceptance criteria along with performance monitoring and human-in-loop controls should be considered. Additionally, model validation should use high quality traceable data and confidence thresholds should be established. The draft Annex 22 can be found here. Additionally, here at PSC Software, we have a team of AI experts ready to answer your questions about AI. 

Regulatory Developments in the Middle East 

GCC Medical Device Harmonization Efforts 

The GCC Standardization Organization, represented by the Gulf Technical Committee for Medical Devices and Supplies, signed a Technical Cooperation Agreement with the European Committee for Standardization, represented by the European Technical Committee for Non-active Medical Devices, in late October 2025. 

Per the release, this agreement aims to harmonize standards for medical devices such as blood pressure monitors, thermometers, catheters, and more. This is the sixth Technical Cooperation Agreement signed by the GSO to increase the harmonization between them and European regulatory bodies, with others covering materials including oil and gas, plastics and rubber, and air conditioning equipment. 

This update means that medical device firms looking to enter the market overseen by the GCC must comply with harmonized requirements in their QMS and documentation, and in some cases, may require local representatives and bilingual labeling to adhere to local requirements. For more information on this, visit the official GCC Standardization Organization website.

Saudi Arabia’s Rapid SFDA Policies 

Since Saudi Arabia’s establishment of the Saudi Food and Drug Authority (SFDA), there have been rapid updates and evolutions in the Kingdom’s regulatory oversight. 

Between 2024 and 2025, several significant updates were posted by the SFDA, covering regulated industries such as medical devices (MDS-G002) and their clinical trial requirements (MDS-REQ 2), Guideline of Good Storage and Distribution Processes (GSDP), and Regulatory Framework for Drugs Approval. The SFDA is looking to ensure more consistent enforcement with increased post-market activities, and stronger regulatory oversight across health product categories. 

Saudi Arabia is an emerging and rapidly expanding market, and right now is an excellent opportunity for businesses to establish themselves in the country. Firms should look to monitor SFDA initiatives and actively engage with their public consultations. Many of the standards in place will be harmonized with other regulatory bodies, and as such compliance frameworks can be readily modified to meet reporting obligations and submission platform requirements with relative ease. Regulations, news, and updates from the SFDA can be found on their official website here.  

Conclusion 

Collectively, these updates reflect a global trend toward harmonization, digitalization, and risk-based compliance. For companies operating in these regions, regulatory agility, robust quality systems, and proactive engagement with authorities will be essential to maintaining market access. Whether it’s adapting to new trial governance in the UK, preparing for EUDAMED requirements in the EU, implementing Annex 22 AI controls, or navigating SFDA’s evolving frameworks, firms should act to align processes, technology, and talent with these emerging standards. 

For more detailed insights and practical compliance solutions, take a look through our solutions. PSC Software is a leading provider of electronic quality management systems (eQMS) and aims to help life sciences organizations stay audit-ready, manage risk, and meet global compliance requirements efficiently. Our platform, ACE, offers integrated tools for document control, training, and quality processes, empowering companies to turn regulatory challenges into competitive advantages.